A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia
Monforte, Antonella d'Arminio
Gavioli, Elizabeth M.
de Pizzol, Maria
GroupSbarro Health Research Organization (Temple University)
Permanent link to this recordhttp://hdl.handle.net/20.500.12613/8083
MetadataShow full item record
AbstractAcute lung injury and acute respiratory distress syndrome are common complications in patients with coronavirus disease 2019 (COVID-19). Poor outcomes in patients with COVID-19 are associated with cytokine release syndrome. Binding of interleukin-8 (CXCL8/IL-8) to its chemokine receptors, CXCR1/2, may mediate this inflammatory process. The aim of this clinical trial was to determine if CXCR1/2 blockade with reparixin can improve clinical outcomes in hospitalized patients with severe COVID-19 pneumonia. The dose and safety of reparixin have been investigated in clinical trials of patients with metastatic breast cancer.
CitationLandoni, G., Piemonti, L., Monforte, A.d. et al. A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia. Infect Dis Ther 11, 1559–1574 (2022). https://doi.org/10.1007/s40121-022-00644-6
Citation to related workSpringer
Has partInfectious Diseases and Therapy, Vol. 11
ADA complianceFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact email@example.com
Except where otherwise noted, this item's license is described as Attribution-NonCommercial CC BY-NC